Verona Pharma

192 articles about Verona Pharma

• Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

  9/11/2023

  Verona Pharma plc, announces the US Food and Drug Administration has accepted for review the Company’s New Drug Application seeking approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.

• Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

  9/6/2023

  Verona Pharma plc, announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease will be presented at the European Respiratory Society International Congress 2023.

• Christina Ackermann Joins Verona Pharma as Non-Executive Director

  8/31/2023

  Verona Pharma plc, announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director.

• Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/3/2023

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2023, and provides a corporate update.

• Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

  7/26/2023

  Verona Pharma plc announces that senior management will present a company overview at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 12:00 PM EDT / 5:00 PM BST.

• Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

  7/20/2023

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

• Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

  6/28/2023

  Verona Pharma plc, announces the American Journal of Respiratory and Critical Care Medicine has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease.

• Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

  6/27/2023

  Verona Pharma plc announces the submission of a New Drug Application to the US Food and Drug Administration for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.

• Verona Pharma to Present at Jefferies Healthcare Conference - May 24, 2023

  5/24/2023

  Verona Pharma plc, announces that senior management will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 AM EDT / 1:00 PM BST.

• Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/9/2023

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.

• Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

  5/2/2023

  Verona Pharma plc announces 12 abstracts, including a mini symposium, and a clinical trials symposium, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease have been accepted by the American Thoracic Society International Conference 2023.

• Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

  4/25/2023

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

• Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

  4/10/2023

  Verona Pharma plc announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease.

• Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/7/2023

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2022, and provides a corporate update.

• Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

  2/21/2023

  Verona Pharma plc announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

• 

  Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data

  12/20/2022

  Verona Pharma's COPD candidate hits the mark in late-stage testing.

• Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

  12/20/2022

  Verona Pharma plc, announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

• Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

  12/19/2022

  Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized ensifentrine on Tuesday, December 20, 2022.

• Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/9/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2022, and provides a corporate update.

• Verona Pharma Announces November 2022 Investor Conference Participation

  11/2/2022

  Verona Pharma plc, announces that senior management will participate in the following conferences in November 2022.